Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

P. Patel, Sapna; Othus, Megan; Chen, Yuanbin; Paul Wright, G.; J. Yost, Kathleen; Hyngstrom, John; Hu‐Lieskovan, Siwen; D. Lao, Christopher; A. Fecher, Leslie; Truong, Thach‐Giao; L. Eisenstein, Jennifer; Chandra, Sunandana; A. Sosman, Jeffrey; Kendra, Kari; C. Wu, Richard; Devoe, Craig; B. Deutsch, Gary; Hegde, Aparna; Khalil, Maya; Mangla, Ankit; M. Reese, Amy; I. Ross, Merrick; Poklepovic, Andrew; Q. Phan, Giao; A. Onitilo, Adedayo; G. Yasar, Demet; Powers, Benjamin; C. Doolittle, Gary; K. In, Gino; Kokot, Niels; T. Gibney, Geoffrey; B. Atkins, Michael; Shaheen, Montaser; Warneke, James; P. Ikeguchi, Alexandra; Eugenio Najera, Jose; Chmielowski, Bartosz; G. Crompton, Joseph; D. Floyd, Justin; C. Hsueh, Eddy; Margolin, Kim; Chow, Warren; F. Grossmann, Kenneth; Dietrich, Eliana; G. Prieto, Víctor; Lowe, Michael; I. Buchbinder, Elizabeth; M. Kirkwood, John; A. Korde, Larissa; Moon, James; Sharon, Elad; K. Sondak, Vernon; Ribas, Antoni

doi:10.1056/nejmoa2211437

Public

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Published in New England Journal of Medicine • Mar 1, 2023

Authors:

Sapna P. Patel

Megan Othus

Yuanbin Chen

Abstract

BACKGROUND: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown. METHODS: In a...

Subject

Medicine

Pembrolizumab

Adjuvant therapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!